Critical Care
Review: Timing and completeness of revascularization in acute coronary syndromes.
26 Jul, 2021 | 02:21h | UTCTiming and completeness of revascularisation in acute coronary syndromes – Heart
Commentary on Twitter
Education: Timing and completeness of revascularisation in acute coronary syndromes https://t.co/VBQ76c3545 pic.twitter.com/tpNaZfhrxI
— Heart_BMJ (@Heart_BMJ) July 22, 2021
Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.
23 Jul, 2021 | 10:51h | UTCTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients.
23 Jul, 2021 | 10:47h | UTC
Review: Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit.
23 Jul, 2021 | 10:30h | UTC
Review: Ethics in extracorporeal life support.
23 Jul, 2021 | 10:29h | UTCEthics in extracorporeal life support: a narrative review – Critical Care
Review: The routes of administration for acute postoperative pain medication.
22 Jul, 2021 | 10:46h | UTCThe Routes of Administration for Acute Postoperative Pain Medication – Pain and Therapy
Review: Personalized mechanical ventilation in acute respiratory distress syndrome.
22 Jul, 2021 | 10:40h | UTCPersonalized mechanical ventilation in acute respiratory distress syndrome – Critical Care
Related: M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies. AND Seminar | Acute respiratory distress syndrome. AND Short review: Diagnosis and management of acute respiratory distress syndrome
RCT: Immediate oral refeeding in patients with mild and moderate acute pancreatitis.
22 Jul, 2021 | 10:32h | UTCImmediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial) – Annals of Surgery (link to abstract – $ for full-text)
A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.
22 Jul, 2021 | 10:37h | UTC
Commentary on Twitter
✨If you have Staph in urine check blood culture✨
?Excellent narrative review on the role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia
Epidemiology and pathogenesis of SABU in patients with SAB? #IDTwitter #ofid https://t.co/wioI3I528z pic.twitter.com/54jVQEBeDW— Antibiotic Steward ???Bassam Ghanem (@ABsteward) March 30, 2021
Expert review | Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy.
21 Jul, 2021 | 10:37h | UTC
Commentary on Twitter
AJOG Expert Review in Preeclampsia: Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy https://t.co/xdZbn51ymU pic.twitter.com/N90GdbdBBw
— AJOG (@AJOG_thegray) July 20, 2021
Cohort study: Sickle cell disorders and severe COVID-19 outcomes – “Our analysis estimated a 4-fold increased risk for COVID-19–related hospitalization and a 2.6-fold increased risk for COVID-19–related death for sickle cell disease”.
21 Jul, 2021 | 10:44h | UTCSickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine
ICU Survivorship—The relationship of delirium, sedation, dementia, and acquired weakness.
21 Jul, 2021 | 10:32h | UTC
WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).
20 Jul, 2021 | 10:29h | UTCRelated Guidance: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” AND ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia
International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.
20 Jul, 2021 | 10:21h | UTCRelated: SARS-CoV-2 and Stroke Characteristics – higher rate of large vessel occlusions and stroke in young patients AND Case series of 18 male adults aged 50 years or younger with acute ischemic stroke during the convalescent phase of asymptomatic Covid-19 AND Case-control study: COVID-19-associated stroke is associated with worse outcomes and increased mortality AND Pictorial essay: Neurological emergencies associated with COVID-19: stroke and beyond AND Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke AND Risk of Ischemic Stroke in Patients with COVID-19 vs. Patients with Influenza
WHO warns that HIV infection increases risk of severe and critical COVID-19.
20 Jul, 2021 | 10:24h | UTCNews release: WHO warns that HIV infection increases risk of severe and critical COVID-19 – World Health Organization
Commentary on Twitter (thread – click for more)
? report confirms that #HIV infection is a significant independent risk factor for both severe/critical #COVID19 presentation at hospital admission & in-hospital mortality. 23.1% of all people living with HIV who were hospitalized with COVID-19, died.
? https://t.co/UBd0OyFKnd pic.twitter.com/UHLo9RPa1g
— World Health Organization (WHO) (@WHO) July 16, 2021
RCT: more data showing Azithromycin is not better than placebo in patients with Covid-19.
18 Jul, 2021 | 23:54h | UTCRelated: RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19. (several articles on the subject)
Commentary on Twitter
Among outpatients with #SARSCoV2 infection, treatment with a single dose of oral #azithromycin compared with placebo did not result in a greater likelihood of being free of symptoms at day 14 https://t.co/dYDcSyGtwd #COVID19
— JAMA (@JAMA_current) July 16, 2021
Review: Acute kidney injury.
18 Jul, 2021 | 23:18h | UTCAcute kidney injury – Nature Reviews Disease Primers (free for a limited period)
Commentary on Twitter
Get Primed on #AcuteKidneyInjury with our NEW PrimeView, FREE to download this week https://t.co/4RAOOaB8ep pic.twitter.com/d5iHCcqJwY
— Nature Reviews Disease Primers (@DiseasePrimers) July 15, 2021
Short review: The gut in COVID-19.
16 Jul, 2021 | 10:54h | UTCThe gut in COVID-19 – Intensive Care Medicine
Commentary on Twitter
Gut & #COVID19, main findings
➡️clinical GI features
➡️pathophysiology: cytotoxic enterocyte injury, microvascular injury/thromboinfammation, non‑specifc critical illness‑related dysfunction
➡️GI dysfunction in severe #SARSCoV2 vs other critical illnesseshttps://t.co/wzzTNldInN pic.twitter.com/DnHLMsSu6v— Intens Care Med (@yourICM) July 9, 2021
Pathophysiology of COVID-19-associated acute kidney injury.
16 Jul, 2021 | 10:52h | UTCPathophysiology of COVID-19-associated acute kidney injury – Nature Reviews Nephrology
M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies.
16 Jul, 2021 | 10:43h | UTC
Review: Sedation in the Intensive Care Unit.
16 Jul, 2021 | 10:31h | UTCSedation in the Intensive Care Unit – Current Anesthesiology Reports
M-A: Utility of intravenous Alteplase prior to endovascular stroke treatment.
15 Jul, 2021 | 09:03h | UTCUtility of Intravenous Alteplase Prior to Endovascular Stroke Treatment: A Systematic Review and Meta-analysis of RCTs – Neurology (link to abstract – $ for full-text)
Commentary: Direct thrombectomy, bridging therapy confer similar functional outcomes in stroke – Healio (free registration required)
Commentary on Twitter
Via @GreenJournal: For #patients with acute large vessel occlusion, functional outcomes were similar for those receiving direct #endovascular treatment and bridging therapy.#NeuroTwitter #neurology https://t.co/LweNGwOhVB pic.twitter.com/jqgZyV9ZOA
— Neurology Today (@NeurologyToday) June 22, 2021
RCT: Lopinavir-ritonavir and hydroxychloroquine worsened outcomes in critically ill patients with COVID-19.
14 Jul, 2021 | 11:25h | UTC
Commentary on Twitter (thread – click for more)
Results of @remap_cap #Covid_19 #Antiviral Domain released Online First @yourICM: Among critically ill patients with COVID-19, #lopinavir-ritonavir, #HydroxyChloroquine, or combination therapy worsened outcomes compared to no antiviral therapy
— remap-cap (@remap_cap) July 13, 2021
RCT: Neither Remdesivir nor Hydroxychloroquine affect viral clearance in hospitalized patients with COVID-19.
14 Jul, 2021 | 11:23h | UTCNews release: Neither remdesivir nor HCQ affect viral clearance in hospitalized patients with COVID-19 – American College of Physicians
Original Study: Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 – Annals of Internal Medicine
Commentary on Twitter
Newly published research in Annals concludes neither remdesivir nor #hydroxychloroquine affected viral clearance in hospitalized patients with #COVID19 https://t.co/K3qWLUW8uY. pic.twitter.com/ugbjJJ3qI5
— Annals of Int Med (@AnnalsofIM) July 12, 2021
FDA Safety Alert: hydroxyethyl starch products should not be used unless adequate alternative treatment is unavailable.
14 Jul, 2021 | 10:48h | UTCCommentary: FDA Piles on New Warnings for Blood Volume Expanders – MedPage Today (free registration required)
Related: Hydroxyethyl-starch Solutions (HES) Should no Longer be Used – European Medicines Agency AND Randomized Trial: Hydroxyethyl Starch vs. Saline for Volume Replacement Therapy in High-Risk Patients Undergoing Major Abdominal Surgery AND Systematic Review: Colloids vs Crystalloids for Fluid Resuscitation in Critically Ill People